Stroke numbers in the United States and the medical costs associated with care are staggering. What's more, a lack of consistent application of best practices still affects treatment. That's why The National Stroke Education Center (NSEC) developed a stroke education resource to bridge the gap.
How do we implement ANNEXXa-I into our Clinical Practice?
For acute care physicians, anticoagulated patients presenting with intracranial hemorrhage (ICH) is an incredibly challenging clinical scenario. ANNEXa-I is a randomized, controlled, clinical trial which provides clinicians with important information on appropriate reversal of anticoagualtion to optimally care for these patients.
Real World Evidence for Management of Severe Bleeding in the Anticoagulated Patient: Impact of Specific Reversal Therapy for Intracranial Hemorrhage and Gastrointestinal Bleeding
Real World studies can provide the foundational support necessary for clinicians to effectively manage anticoagulated patients with severe, often life-threatening intracranial and gastrointestinal bleeding. While randomized controlled clinical trials have provided the initial data necessary for appropriate use of reversal agents such as andexanet alfa for Factor Xa associated bleeding, broader studies enrolling thousands of patients, many with significant co-morbidities, are extremely valuable to clinicians. New information regarding the randomized controlled trial ANEXXA-I, which was halted due to andexanet alfa efficacy, provides additional information supporting reversal therapy for severe bleeding.
The Role of Real World Evidence in Driving Clinical Care for Anticoagulated Patients with Life-Threatening Bleeding
Experts in Emergency Medicine, Pharmacy, and Neurocritical Care describe the impact of real world evidence on the care of life-threatening bleeding in the anticoagulated patient. While clinical trial data remain the standard for clinicians, real world data provide important additional information on the use of a particular Repletion or Reversal therapy for these patients.
What Are the Barriers to Success When Implementing Care Pathways for ICH Patients?
ICH remains deadly and pathways matter but they aren't always what we need and barriers can be overcome with knowledge.
How Do We Coordinate Care Within Our Hospitals To Improve Outcomes in Hemorrhagic Stroke Patients?
Coordinating the necessary care for hemorrhagic patients is complicated- learn the ropes from experts on the UC Stroke Team. "Smoother, faster better" is the name of the game.
Are We Prepared To Manage Anticoagulated ICH Patients or Should We Direct Them Elsewhere?
How and where to treat ICH patients- politics, reversal agents, and science all in one podcast!